


CIRM Funded Clinical Trials

## Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients

<b>Disease Area:</b>	HIV-related Lymphoma, HIV/AIDS
<b>Investigator:</b>	Mehrdad Abedi
<b>Institution:</b>	University of California, Davis
<b>CIRM Grant:</b>	CLIN2-08289
<b>Award Value:</b>	\$8,414,265
<b>Trial Sponsor:</b>	AIDS Malignancy Consortium
<b>Trial Stage:</b>	Phase 1/2
<b>Trial Status:</b>	Suspended
<b>Targeted Enrollment:</b>	18
<b>ClinicalTrials.gov ID:</b>	NCT02797470



Mehrdad Abedi

### Details:

A team at UC Davis is taking a patient's blood forming stem cells and inserting three anti-HIV genes into them and then returning them to the individual to help rebuild their immune system. The anti-HIV genes are then passed on to all new immune system cells, which makes them resistant to HIV. Because AIDS-related lymphoma is linked to the constant immune cell stimulation caused by HIV infection, getting rid of the virus should prevent return of the cancer.

### Design:

Open label, single arm study.

### Goal:

Safety. Efficacy - immune reconstitution, viral load and HIV status.

### Updates:

This study has suspended participant recruitment.

[Contact Trial Sponsor](#)